News - Spectrum Pharmaceuticals

Filter

Current filters:

Spectrum Pharmaceuticals

Popular Filters

Bladder cancer market to witness moderate growth by 2017, despite anticipated launch of EOoquin

Bladder cancer market to witness moderate growth by 2017, despite anticipated launch of EOoquin

22-01-2014

The bladder cancer therapeutics market in the six major countries is forecast to climb from $239.3 million…

EOquinEuropeMarkets & MarketingOncologyPharmaceuticalSpectrum PharmaceuticalsUSA

Spectrum Pharma adds to hematology and oncology portfolio with acquisition

18-07-2013

US biotech firm Spectrum Pharmaceuticals (Nasdaq: SPPI) says that it has entered into an agreement to…

BiotechnologyMarqiboMenadioneMergers & AcquisitionsSpectrum PharmaceuticalsTalon Therapeutics

Ligand to earn up to $50 million in deal with Spectrum for Captisol-enabled melphalan

14-03-2013

Ligand Pharmaceuticals (Nasdaq: LGND) has signed a global license and supply agreements with fellow US…

FinancialLicensingLigand PharmaceuticalsmelphalanOncologyPharmaceuticalSpectrum Pharmaceuticals

Global epigenetic therapies market to increase at a CAGR of 10% through 2017

04-03-2013

The global epigenetic therapies market is expected to reach a total value of around $2.518 billion by…

belinostatBiotechnologyCelgeneFaridakGlobalMarkets & MarketingNovartisOncologypanobinostatPharmaceuticalSpectrum PharmaceuticalsTopotargetVidaza

Spectrum regains rights from Allergan for apaziquone

03-02-2013

US biotech firm Spectrum Pharmaceuticals (NasdaqGS: SPPI) says it has reacquired development and commercialization…

AllerganapaziquoneBiotechnologyLicensingOncologyResearchSpectrum Pharmaceuticals

Topotarget says belinostat pivotal trial meets primary endpoint

26-09-2012

Denmark's Topotarget (Nasdaq OMX: TOPO) said that the primary endpoint has been met for the pivotal trial…

belinostatOncologyPharmaceuticalResearchSpectrum PharmaceuticalsTopotarget

Spectrum extends tender offer for Allos

09-07-2012

US biotech firm Spectrum Pharmaceuticals (Nasdaq: SPPI) said late Friday that it has again extended tender…

Allos TherapeuticsBiotechnologyFolotynMergers & AcquisitionsOncologySpectrum Pharmaceuticals

Spectrum plunges on negative trial results; makes bid for Allos

10-04-2012

US biotech firm Spectrum Pharmaceuticals (Nasdaq: SPPI) saw its shares plunge as much as 14%, before…

Allos TherapeuticsapaziquoneBiotechnologyFolotynMergers & AcquisitionsOncologyPharmaceuticalResearchSpectrum Pharmaceuticals

Spectrum in-licenses novel GCSF drug from Hanmi Pharma

01-02-2012

USA-based Spectrum Pharmaceuticals (NasdaqGS: SPPI) has entered into a co-development and commercialization…

Hanmi PharmaceuticalLicensingOncologyPharmaceuticalSpectrum Pharmaceuticals

Spectrum Pharma to acquire non-US rights to market Zevalin

26-01-2012

USA-based Spectrum Pharmaceuticals (NasdaqGS: SPPI) says it has entered into an agreement to acquire…

BayerMergers & AcquisitionsOncologyPharmaceuticalSpectrum PharmaceuticalsZevalin

Spectrum upbeat on lymphoma drug Zevalin study

24-01-2012

US biotech firm Spectrum Pharmaceuticals (NasdaqGS: SPPI) yesterday announced results of a randomized…

BiotechnologyOncologyResearchSpectrum PharmaceuticalsZevalin

Back to top